<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088358</url>
  </required_header>
  <id_info>
    <org_study_id>CV-TRX-01</org_study_id>
    <nct_id>NCT03088358</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement</brief_title>
  <official_title>A Multicenter, Randomized, Pilot, Dose-Ranging Clinical Study to Evaluate Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TeaRx LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TeaRx LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate influence of therapy on the following efficacy and safety parameters in different
      TeaRx dose groups and Enoxaparin group:

        -  Total venous thromboembolic events (VTE), which includes confirmed deep venous
           thrombosis (DVT), nonfatal pulmonary embolism (PE), and total mortality

        -  Incidence of DVT (total, proximal, distal)

        -  Incidence of nonfatal PE

        -  Incidence of symptomatic VTE (DVT, PE)

        -  VTE caused mortality

        -  Non-VTE caused mortality

        -  Incidence of all hemorrhagic complications

        -  Incidence of major and clinically relevant non-major bleeding

        -  Adverse events (AEs) and serious adverse events (SAEs) from subject complaints, physical
           examination, vital signs, laboratory results
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of deep venous thrombosis (DVT) (efficacy of the selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of nonfatal pulmonary embolism (PE) (efficacy of the selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of symptomatic venous thromboembolic events (DVT, PE) (efficacy of the selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>venous thromboembolic events (VTE) caused mortality (efficacy of the selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-VTE caused mortality (efficacy of the selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs and SAEs from subject complaints, physical examination, vital signs, laboratory results (efficacy of the selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding (safety of selected TeaRx dose)</measure>
    <time_frame>6 weeks following total knee replacement</time_frame>
    <description>major and clinically relevant non-major bleeding</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Total Knee Replacement</condition>
  <arm_group>
    <arm_group_label>TeaRx 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TeaRx 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TeaRx 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TeaRx</intervention_name>
    <arm_group_label>TeaRx 50 mg</arm_group_label>
    <arm_group_label>TeaRx 100 mg</arm_group_label>
    <arm_group_label>TeaRx 150 mg</arm_group_label>
    <other_name>TeaRxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>Enoxaparin</arm_group_label>
    <other_name>Clexane ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age ≥ 18 years;

          -  Planned total knee replacement surgery;

          -  Signed informed consent form;

          -  Willing to comply with the protocol;

          -  Willing to use adequate contraception during the trial.

        Exclusion Criteria:

          -  Surgery for acute fracture 4 weeks before screening; history of septic inflammation in
             the joint; prosthesis revision or one leg missing

          -  History of venous thrombosis of any location or PE

          -  History of heparin induced thrombocytopenia or other thrombocytopathy; hemorrhagic
             diathesis

          -  History of evident coagulopathy or in a relative

          -  Congenital thrombophilia

          -  Bleeding within 6 months of screening; increased risk of bleeding

          -  BMI less than 18,5 or more than 40 kg/m2

          -  Systolic BP &gt; 180 mmHg and/or diastolic BP &gt; 110 mmHg registered twice within 15-30
             minutes

          -  Hb ≤ 10.5 g/dL in female or ≤ 11.5 g/dL in male

          -  Platelets &lt; 100 000/mm3

          -  Clinical significant abnormalities of APTT and/or INR

          -  GFR &lt; 30 ml/min/1.73 m2

          -  ALT or AST ≥ 2 x ULN or total bilirubin ≥1,5 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail N. Zamyatin, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Federal State Institution &quot;National Medical and Surgical Center n. a. N. I. Pirogov&quot; of the Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SHAI &quot;Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan&quot;</name>
      <address>
        <city>Kazan</city>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;National Medical and Surgical Center n. a. N. I. Pirogov&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE First Moscow State Medical University n.a. I.M. Sechenov Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI of the city of Moscow City Clinical Hospital n.a. S.P. Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Nizhny Novgorod Research Institute of Traumatology and Orthopedics&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;City Clinical Hospital № 4&quot; of the city of Orenburg</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Institution of Health &quot;City Hospital № 2&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI of the Yaroslavl Region Emergency care hospital n. a. N. V. Solovyov</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>March 18, 2017</last_update_submitted>
  <last_update_submitted_qc>March 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

